B
BioFactura
Biopharmaceutical research and manufacturing company
About BioFactura
BioFactura, Inc. is a biopharmaceutical company specializing in the development and manufacturing of high-value biosimilars, biodefense medical countermeasures, and client-selected novel drugs. The company operates in the global biomedical and national biodefense markets, addressing unmet needs through its proprietary StableFastTM Biomanufacturing Platform. This platform enables rapid and stable production of biosimilars and other biologics, enhancing efficiency and reducing costs. BioFactura's business model involves partnering with healthcare networks, legal firms, and other stakeholders to secure investments and contracts, such as the recent $67.4 million advanced development contract for a smallpox biodefense therapeutic. The company generates revenue through the development and sale of its biopharmaceutical products and services, catering to clients in the healthcare and biodefense sectors.
Source: Dealroom company dataNews
Open roles
BioFactura in the Frederick ecosystem
The BioFactura office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US Biomedical Advanced Research and Development Authority
US Department of War
Series A2 investors entered at this stage
Jeffrey Hausfeld
Wilson Sonsini
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BioFactura on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BioFactura on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
